1
|
Quaife NM, Chothani S, Schulz JF, Lindberg EL, Vanezis K, Adami E, O'Fee K, Greiner J, Litviňuková M, van Heesch S, Whiffin N, Hubner N, Schafer S, Rackham O, Cook SA, Barton PJR. LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide. J Cardiovasc Transl Res 2023; 16:77-85. [PMID: 35759180 PMCID: PMC9944705 DOI: 10.1007/s12265-022-10288-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 06/09/2022] [Indexed: 10/17/2022]
Abstract
Myocardial fibrosis confers an almost threefold mortality risk in heart disease. There are no prognostic therapies and novel therapeutic targets are needed. Many thousands of unannotated small open reading frames (smORFs) have been identified across the genome with potential to produce micropeptides (< 100 amino acids). We sought to investigate the role of smORFs in myocardial fibroblast activation.Analysis of human cardiac atrial fibroblasts (HCFs) stimulated with profibrotic TGFβ1 using RNA sequencing (RNA-Seq) and ribosome profiling (Ribo-Seq) identified long intergenic non-coding RNA LINC01013 as TGFβ1 responsive and containing an actively translated smORF. Knockdown of LINC01013 using siRNA reduced expression of profibrotic markers at baseline and blunted their response to TGFβ1. In contrast, overexpression of a codon-optimised smORF invoked a profibrotic response comparable to that seen with TGFβ1 treatment, whilst FLAG-tagged peptide associated with the mitochondria.Together, these data support a novel LINC01013 smORF micropeptide-mediated mechanism of fibroblast activation. TGFβ1 stimulation of atrial fibroblasts induces expression of LINC01013, whose knockdown reduces fibroblast activation. Overexpression of a smORF contained within LINC01013 localises to mitochondria and activates fibroblasts.
Collapse
Affiliation(s)
- N M Quaife
- National Heart and Lung Institute, Imperial College London, London, UK
- MRC London Institute of Medical Sciences, London, UK
| | - S Chothani
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
| | - J F Schulz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - E L Lindberg
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K Vanezis
- National Heart and Lung Institute, Imperial College London, London, UK
- MRC London Institute of Medical Sciences, London, UK
| | - E Adami
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K O'Fee
- MRC London Institute of Medical Sciences, London, UK
| | - J Greiner
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - M Litviňuková
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - S van Heesch
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - N Whiffin
- National Heart and Lung Institute, Imperial College London, London, UK
- Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy's and St Thomas NHS Foundation Trust, London, UK
- Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
| | - N Hubner
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S Schafer
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
| | - O Rackham
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
| | - S A Cook
- MRC London Institute of Medical Sciences, London, UK
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
- National Heart Centre Singapore, Singapore, Singapore
| | - P J R Barton
- National Heart and Lung Institute, Imperial College London, London, UK.
- MRC London Institute of Medical Sciences, London, UK.
- Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy's and St Thomas NHS Foundation Trust, London, UK.
| |
Collapse
|
2
|
Quaife NM, Chothani S, Schulz JF, Lindberg EL, Vanezis K, Adami E, O’Fee K, Greiner J, Litviňuková M, van Heesch S, Whiffin N, Hubner N, Schafer S, Rackham O, Cook SA, Barton PJR. Correction to: LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide. J Cardiovasc Transl Res 2023; 16:86. [PMID: 35834119 PMCID: PMC9944001 DOI: 10.1007/s12265-022-10291-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- N. M. Quaife
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK
| | - S. Chothani
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore
| | - J. F. Schulz
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany ,grid.452396.f0000 0004 5937 5237DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - E. L. Lindberg
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K. Vanezis
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK
| | - E. Adami
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore ,grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K. O’Fee
- grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK
| | - J. Greiner
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - M. Litviňuková
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - S. van Heesch
- grid.487647.ePrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - N. Whiffin
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.420545.20000 0004 0489 3985Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas NHS Foundation Trust, London, UK ,grid.4991.50000 0004 1936 8948Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
| | - N. Hubner
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany ,grid.452396.f0000 0004 5937 5237DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany ,grid.484013.a0000 0004 6879 971XBerlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - S. Schafer
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore
| | - O. Rackham
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore
| | - S. A. Cook
- grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK ,grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore ,grid.419385.20000 0004 0620 9905National Heart Centre Singapore, Singapore, Singapore
| | - P. J. R. Barton
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK ,grid.420545.20000 0004 0489 3985Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas NHS Foundation Trust, London, UK
| |
Collapse
|
3
|
Reichart D, Lindberg EL, Maatz H, Miranda A, Viveiros A, Shvetsov N, Lee M, Kanemaru K, Milting H, Noseda M, Oudit G, Heinig M, Seidman JG, Huebner N, Seidman CE. Pathogenic variants damage cell compositions and single cell transcription in cardiomyopathies. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Pathogenic variants in genes that cause dilated (DCM) and arrhythmogenic cardiomyopathies (ACM) convey high risks for the development of heart failure (HF) through unknown mechanisms. Using single nucleus RNA sequencing (snRNAseq), we characterized the transcriptome of 880,000 nuclei from 18 control and 61 failing, non-ischemic human hearts with pathogenic variants in DCM and ACM genes or idiopathic disease. We performed genotype-stratified analyses of the ventricular cell lineages and transcriptional states. The resultant DCM and ACM ventricular cell atlas demonstrated distinct right and left ventricular responses, highlighting genotype-associated pathways, intercellular interactions, and differential gene expression at single cell resolution. Together these data illuminate both shared and distinct cellular and molecular architectures of human HF and suggest novel candidate therapeutic targets.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Chan Zuckerberg FoundationLeducq Foundation
Collapse
Affiliation(s)
- D Reichart
- Harvard Medical School , Boston , United States of America
| | - E L Lindberg
- Max Delbruck Center for Molecular Medicine , Berlin , Germany
| | - H Maatz
- Max Delbruck Center for Molecular Medicine , Berlin , Germany
| | - A Miranda
- Imperial College London , London , United Kingdom
| | - A Viveiros
- Mazankowski Alberta Heart Institute , Edmonton , Canada
| | - N Shvetsov
- Max Delbruck Center for Molecular Medicine , Berlin , Germany
| | - M Lee
- Imperial College London , London , United Kingdom
| | - K Kanemaru
- Wellcome Trust Sanger Institute , Hinxton , United Kingdom
| | - H Milting
- Herz- und Diabeteszentrum NRW, Ruhr-Universitaet Bochum , Bad Oeynhausen , Germany
| | - M Noseda
- Imperial College London , London , United Kingdom
| | - G Oudit
- Mazankowski Alberta Heart Institute , Edmonton , Canada
| | - M Heinig
- Helmholtz Center Munich , Neuherberg , Germany
| | - J G Seidman
- Harvard Medical School , Boston , United States of America
| | - N Huebner
- Max Delbruck Center for Molecular Medicine , Berlin , Germany
| | - C E Seidman
- Harvard Medical School , Boston , United States of America
| |
Collapse
|